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Abstract
AIM: To test the hypothesis that enhancement of the 
activity of heme oxygenase can interfere with processes 
of fibrogenesis associated with recurrent liver injury, we 
investigated the therapeutic potential of over-expression 
of heme oxygense-1 in a CCl4-induced micronodular cir-
rhosis model. 
Methods: Recombinant adeno-associated viruses car-
rying rat HO-1 or GFP gene were generated. 1×1012 vg 
of adeno-associated viruses were administered through 
portal injection at the time of the induction of liver fi-
brosis. 
Results: Conditioning the rat liver with over-expres-
sion of HO-1 by rAAV/HO-1 significantly increased the 
HO enzymatic activities in a stable manner. The develop-
ment of micronodular cirrhosis was significantly inhib-
ited in rAAV/HO-1-transduced animals as compared to 
controls. Portal hypertension was markedly diminished 
in rAAV/HO-1-transduced animals as compared to con-
trols, whereas there are no significant changes in systolic 
blood pressure. This finding was accompanied with im-
proved liver biochemistry, less infiltrating macrophages 
and less activated hepatic stellate cells (HSCs) in rAAV/
HO-1-transduced livers. 
ConClusIons: Enhancement of HO activity in the liv-
ers suppresses the development of cirrhosis. 
© 2006 The WJG Press. All rights reserved.
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IntroductIon
Heme oxygenase (HO) is a rate-limiting enzyme that 
cleaves pro-oxidant heme into equimolar amounts of  
carbon monoxide (CO), biliverdin/bilirubin, and free 
ferrous iron [1,2]. Up to date, three isoforms of  HO have 
been identified. Among of  them, HO-1 and HO-2 are 
expressed in livers. HO-2 expresses constitutively in hepa-
tocyte and functions as an important enzyme in catalyzing 
the endogenous and exogenous heme. In contrast, HO-1 
is an inducible form of  HO in livers [3]. Although expres-
sion of  HO-1 in the liver is primarily restricted to a sub-
population of  Kupffer cells [3,4], the protein is expressed in 
both parenchymal and particularly non-parenchymal liver 
cells, and therefore results in higher enzymatic activities of  
HO under stress conditions [4]. The cytoprotective effects 
of  enhanced HO activities in liver might be through the 
mechanisms associated with its catalytic products. All of  
its three catalytic products can contribute the protective ef-
fects of  HO [5-7]. 
HO-1 was induced in the livers with cirrhosis [8]. 
It was thought to be an adoptive response to oxidative 
stresses, inflammatory insults of  persistent or recurrent 
liver injury as well as the responsiveness to the increase of  
intrasinusoidal resistance. HO-1 was mainly expressed in 
Kupffer cells, sinusoidal endothelial cells, stellate cells and 
in a part of  hepatocyte in livers with cirrhosis [8,9]. HO-1 
was also expressed in vascular system that might contrib-
ute to the development of  hemodynamic changes in the 
rats with cirrhosis [9]. In addition, higher levels of  CO 
production might be associated with the development of  
hepatopulmonary syndrome in patients with cirrhosis [10]. 
Thus, it becomes controversy whether the expression of  
HO-1 or enhancement of  HO activities contribute to the 
pathophysiological changes in the development of  cirrho-
sis, or whether HO-1 functions as homeostatic molecule in 
controlling of  disease progression. To elucidate the role of  
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HO-1 in the context of  recurrent hepatocellular injury and 
the development of  cirrhosis, here we take the advantage 
of  adeno-associated viral vector to increase the overall HO 
enzymatic activity of  the liver in a stable manner and to 
investigate the effects of  HO-1 in the disease progression 
in carbon tetrachloride (CCl4)-induced cirrhosis model. 
MAtErIALS And MEtHodS
Generation of recombinant adeno-associated viral vectors 
(rAAVs) 
rAAVs were produced and purified as previously described [11]. 
In brief, a full-length HO-1 gene originally cloned from 
the spleen of  a LEW rat or the reporter gene GFP was 
inserted into the vector plasmid to construct pSNAV1/
GFP or pSNAV1/HO-1. rAAV/GFP or rAAV/HO-1 was 
generated in BHK-21 cells (American Type Culture Collec-
tion, Manassas, VA) by transfection of  vector plasmid and 
subsequent rescue rAAVs (serotype 2) by co-infection with 
recombinant HSV1-rc/∆UL2, which is essential for viron 
packaging. A large scale of  rAAV was purified as described [12]. 
Animal model and gene delivery protocol
Inbred LEW rats (230-250 g) were purchased from the 
Animal Institute of  Medical School Hannover, Germany 
and were maintained in the Laboratory Animal Unit of  
the University of  Hong Kong. The study was approved by 
the Committee on the Use of  Live Animals for Teaching 
and Research, the University of  Hong Kong. Micronodular 
liver cirrhosis in LEW rats was induced using a protocol 
described previously [13]. In brief, phentobarbital sodium 
(35 mg/L) was given one week before the first dose of  CCl4 
in order to increase the sensitivity of  the rat liver to CCl4 
and was present in drinking water in the whole period of  
induction. A total of  9 doses of  CCl4 (0.2 mL/kg per wk) 
were given to the rats intragastrically. rAAVs (1×1012v.g.) 
was given through the portal vein of  rats at the time pento-
barbital was given in drinking water and 7 d before the first 
dose of  CCl4. 
Liver biochemistry, histology, immunohistochemistry and 
ELISA 
Serum samples were collected at the end point of  experi-
ments. The activities of  alanine aminotransferase (ALT) 
and total bilirubin in the plasma were measured in the 
Department of  Clinical Biochemistry, the University of  
Hong Kong. Liver samples were snap frozen and stored at 
-75 ℃ until further applications. Five micrometers of  fro-
zen sections were used for hematoxylin and eosin staining, 
Masson’s trichrome staining, and immunohistochemistry. 
The area of  fibrotic tissues in the cross section of  livers 
was measured by the computer software (MetaMorph im-
aging system, Universal Imaging Corporation, PA) after 
Masson’s trichrome, collagen 1α and fibronectin staining. 
All measurements were done in a double-blind manner 
with at least 20 areas/liver (fibrotic area, original 200×) 
in the 5 livers/group. Mouse anti-rat ED1 (infiltrating 
macrophage), anti-ED2 (tissue residential macrophage), 
anti-HO-1 (OSA-111) monoclonal antibodies and poly-
clonal anti-TGF-β1, anti-desmin, anti-collagen 1α, and 
anti-fibronectin antibodies (Serotec Ltd., Oxford, UK; 
Stressgene, Victoria, British Columbia, Canada; Chemicon, 
Temecula, CA; Santa Cruz, CA) were applied in this study 
for immunohistochemistry using the standard horseradish 
peroxidase protocol. Serum macrophage migration inhibi-
tory factor (MIF) level was detected by ELISA according 
to the instruction of  manufacturer (Chemicon). 
Measurement of portal and systolic blood pressure
Animals were anesthesized with ketamine (100 mg/kg, ip) 
and Rompun (0.2 mg/kg, ip). Portal pressure and systolic 
blood pressure were measured by directly introducing 24G 
Angiocath® (BD Biosciences, San Jose, CA) into the portal 
vein or abdominal aorta and connecting with a saline filled 
strain gauge transducer. The signals were monitored by 
Colin BP-408 Mark III (Japan) and were set to zero before 
the measurement. 
HO enzymatic activity
The HO enzymatic activity was measured by the produc-
tion of  microsomal bilirubin in the liver. Frozen samples 
of  livers were homogenized in ice-cold sucrose and Tri-
HCl buffer. Microsomal pellet was obtained after centrifu-
gation and was then re-suspended in MgCl2-potassium 
phosphate buffer. Sample protein was further incubated 
with the reaction mixture containing rat liver cytosol, he-
min, glucose-6-phosphate, glucose-6-phosphate dehydro-
genase and NADPH (Sigma-Aldrich, St. Louis, MO) for 
60 minutes at 37 ℃. The generated bilirubin was measured 
using spectrophotometry. The level of  bilirubin produc-
tion was demonstrated by the ratio of  sample/normal 
liver. 
RNase protection assay
The mRNA level of  target genes was determined by 
RNase protection assay according to the instruction of  
manufacturer (RiboQuant kit, BD Biosciences Pharmin-
gen, San Diego, CA). In brief, total RNA of  transduced 
and non-transduced liver samples were extracted and puri-
fied using Rneasy kit (Qiagen, Hilden, Germany). Three 
micrograms of  RNA/samples were hybridized with com-
plimentary [32P]UTP labeled riboprobes overnight. The 
probes were digested with Rnase and were loaded on a 
denatured polyacrylamide gel. The radioactive signals were 
then detected by exposure to X-ray film (BioMax, Kodak, 
Rochester, NY) and quantified by phosphorimaging (Strom, 
Molecular Dynamics, Sunnyvale, CA). 
Statistical analysis
Data were demonstrated as mean ± SEM. One-way ANO-
VA was used to compare the difference of  means between 
the experimental groups with the Bonferroni’s t-test. 
P < 0.05 was considered statistically significant.
rESuLtS 
rAAV-mediated stable HO enzymatic activity in rat liver 
To enhance HO activity in a stable manner, we admin-
istered the rAAV carrying rat HO-1 cDNA to the liver 
through portal injection. After the injection, a large num-
www.wjgnet.com
ber of  HO-1 positive non-parenchymal cells were found in 
both rAAV/GFP and rAAV/HO-1-transduced livers on d 
7 (17.7 ± 0.5 cells/mm2 versus 10.8 ± 0.7 cells/mm2, n = 3). 
However, the number of  positive cells decreased dramati-
cally to a level similar to normal livers in rAAV/GFP 
transduced liver on day 30, whereas there was a signifi-
cantly larger number of  HO-1-positive non-parenchymal 
cells in rAAV/HO-1-transduced livers (3.9 ± 0.8 cells/mm2 
vs 5.8 ± 1.0 cells/mm2, n = 3, P < 0.05; Figures 1A and 1B). 
No HO-1 positive hepatocyte was found in both rAAV/
GFP and rAAV/HO-1 treatment groups on d 7. The ex-
pression of  HO-1 in hepatocyte was first detected sporadi-
cally on d 14 after portal injection of  rAAV/HO-1, where-
as there was no HO-1 positive hepatocyte in rAAV/GFP-
transduced livers (data not shown). More HO-1 positive 
hepatocytes could be detected in rAAV/HO-1-transduced 
livers on d 30 (2.2 ± 0.3 cells/mm2, n = 3, P < 0.05), whereas 
they remained undetectable in rAAV/GFP-transduced liv-
ers (Figures 1A and 1B). To evaluate the biological activity 
of  transduced HO-1 in the livers, we determined the en-
zymatic activity of  HO by measuring the generated biliru-
bin of  microsomal protein isolated from the livers. There 
was a significant increase of  HO activity of  the rAAV-
transduced livers on d 7 (the earliest time point that we 
detected). Both rAAV/GFP and rAAV/HO-1 transduced 
livers showed increased amount of  generated bilirubin in 
isolated microsomal proteins. Impressively, the amount of  
generated bilirubin (0.9 fold over the basal level of  normal 
rat liver) remained elevated in the rAAV/HO-1 treatment 
group and sustained for over 3 mo of  observation time. 
In contrast, the amount of  generated bilirubin decreased 
to the level of  normal rats in the rAAV/GFP treatment 
group on d 14. (Figure 1C). This suggests the specificity of  
rAAV/HO-1 in the induction of  stable HO activity in rat 
liver. 
Enhancement of HO activity suppressed the development 
of cirrhosis in rats 
Intragastrically administration of  CCl4 to adult LEW rats 
for 9 wk resulted in the formation of  micronodular cir-
rhosis. To further evaluate the effects of  elevated HO 
activity on the development of  cirrhosis, we examined 
various parameters relating to cirrhosis after over-expres-
sion of  HO-1 in rat liver by rAAV gene transfer (Figure 
2A). Histological examination showed massive amount 
of  fibrotic tissues accumulated in the portal tract areas of  
non-transduced or rAAV/GFP-transduced livers and led 
to the formation of  micronodular cirrhosis accompanied 
with portal hypertension and lower systolic blood pres-
sure in the majority of  rats. rAAV/HO-1 gene transfer 
markedly diminished the amount of  accumulated fibrotic 
tissues as shown in Masson’s trichrome (MT) staining and 
immunohistochemistry. No micronodular cirrhosis was 
formed and only minimal fibrotic tissues could be found 
in the portal tract areas of  rAAV/HO-1-transduced livers 
(Figure 2B). Analysis of  fibrotic areas using the computer 
software showed that there was significantly less fibrotic 
element deposition in the rAAV/HO-1-transduced liver 
(7.9% ± 0.9% by MT staining, 3.1% ± 2.6% by collagen 1α 
Figure 1  A: The expression patterns of HO-1 in the livers after portal injection of 
rAAV/HO-1 in LEW rats. Red arrow indicated the HO-1-positive non-parenchymal 
cells; green arrow indicated the hepatocyte; B: The quantification of the HO-1 
positive cells in the liver after administration of rAAV/HO-1. Data were presented 
as number of HO-1 positive cells per mm2; n = 3-5, mean ± SE, aP<0.05; C: The 
HO enzymatic activity of rAAV/GFP or rAAV/HO-1 transduced livers. The data 
were demonstrated as the amount of generated bilirubin of microsomal protein 
from liver tissues and were shown as the fold changes over the normal rat liver, 
mean ± SE, n = 3, aP < 0.05. 
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Figure 2  A: The model to induce micronodular cirrhosis in LEW rat. The rAAVs 
were injected through the portal vein shortly before the induction; B: The histology 
and immunohistochemistry of the livers with or without treatment at the 10th 
week (H-E, original magnification ×40; MT: Masson’s trichrome stiaining, the 
fibrotic elements were stained in green, original 100×; collagen 1 and fibronectin 
staining, original magnification ×100); C: The measurement of fibrotic area in 
the livers at the 10th week by the computer software as described in Materials 
& Methods. Data were shown as mean±SE, n = 5, bP < 0.001; D and E: The 
systolic and portal pressure of rats after induction of liver cirrhosis with or without 
treatments. The data were shown as mean±SE, n = 10, dP < 0.001.
staining, 4.4% ± 1.2% by fibronectin staining, P < 0.001). 
In contrast, in the livers of  non-treatment or rAAV/GFP 
treated groups, there was a higher level of  fibrotic ele-
ment deposition (22.2% ± 5.8% or 20.8 %± 3.8% by MT 
staining, 21.9 %± 5.7% or 24.5 %± 2.8% by collagen 1α 
staining, 24.1 %± 4.4% or 21.1% ± 3.6% by fibronectin 
staining, Figure 2C). In addition, the beneficial effects of  
HO-1 on the development of  liver cirrhosis could be re-
flected by the reduction of  portal hypertension (8.0 ± 0.8 
mmHg versus 13.3 ± 0.4 mmHg in the non-treatment 
group and 13.8 ± 0.6 mmHg in the rAAV/GFP treatment 
group, P < 0.001), whereas there was no significant differ-
ence at the systolic blood pressure (81.7 ± 0.3 mmHg) in 
comparison to non-treatment (81.8 ± 0.6 mmHg) or vector 
controls (87.0 ± 0.2 mmHg, P > 0.31, Figures 2D and 2E). 
Stable HO activity protected against CCl4-mediated recur-
rent liver injury
Repeated admi istration of  CCl4 to adult rats led to chron-
ic liver injury with elevated plasma level of  total bilirubin 
(no treatment group: 57.25 ± 6.95 μmol/L; rAAV/GFP 
group: 60.5±4.87 μmol/L) and ALT (non-treatment group: 
4 522 ± 334 IU/L; rAAV/GFP group: 6 552 ± 1 363 IU/L, 
n = 5). Increasing HO activity in the liver by rAAV/HO-1 
significantly improved the liver function of  rats under 
long-term CCl4 toxicity, the amount of  total bilirubin and 
ALT decreased dramatically in the rAAV/HO-1-treated 
rats in comparison to non-treatment or rAAV/GFP con-
trols (total bilirubin: 6.20 ± 3.49 μmol/L; ALT: 199.6 ±
80.5 IU/L, n = 5, P < 0.005, Figures 3A and 3B). To further 
examine the protective effects of  over-expressing HO-1 in 
the livers, we determined the transcript level of  apoptotic 
genes and energy exchanges of  livers under long-term 
CCl4 toxicity. Rnase protection assay showed the transcript 
level of  Fas, caspase 3, and BAX genes significantly dimin-
ished in the rAAV/HO-1-transduced livers (n = 3, P < 0.05, 
www.wjgnet.com
Tsui TY et al . HO-1 suppresses liver fibrogenesis                                                                                               2019
Non-transduced   rAAV/GFP  rAAV/HO-1
M
T
Fi
br
on
ec
tin
Co
lla
ge
n
1
H
&
E
rAAVs
Phenobarbital sodium + CCl4 (10 wk)A
B
0
2
4
6
8
10
12
14
16
No
rm
al
rat
No
n-
tra
n
sd
uc
ed
rA
AV
/G
FP
rA
AV
/H
O-
1
Po
rt
al
pr
es
su
re
(m
m
H
g)
d
E
D
C
Figure 3  A and B: The liver function of rats with or with treatment under long-term 
CCl4 toxicity was presented by the determination of plasma ALT and total bilirubin 
level. The data was shown as mean±SEM, n = 5-10, aP<0.001; C and D: The 
representative picture of the expression patterns of apoptotic genes in the livers at 
the 10th week. The mRNA level of genes was detected by RNase protection assay. 
The quantification of the expression level was measured by phosphoimager as 
described in Materials & Methods. The data were shown as mean ± SE, n = 3-5, 
bP<0.05; E: The ATP level of the livers of rats with or without treatments at the 10th 
wk, n  =  5-10, dP<0.001.
Figures 3C and 3D), whereas these genes were strongly ex-
pressed in the non-transduced or rAAV/GFP-transduced 
livers. The beneficial effects of  HO-1 on CCl4-mediated 
chronic liver injury were also shown by the improvement 
of  liver energy exchanges. Over-expression of  HO-1 by 
rAAV significantly improved the intrahepatic ATP level 
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in rAAV/HO-1transduced liver in comparison with non-
treatment or rAAV/GFP-transduced livers of  rats under 
long-term CCl4 toxicity (n = 3-5, P   < 0.05; Figure 3E). 
Stable HO activity suppresses the pro-inflammatory and 
pro-fibrogenic responses in CCl4-treated rats
To characterize the effects of  HO-1 on the chronic inflam-
matory response followed by liver injury, we examined the 
histopathological parameters of  liver tissues and transcript 
or protein level of  pro-inflammatory cytokine-MIF. A 
large amount of  ED1-positive (infiltrating) macrophages 
accumulated in the portal tract areas in the non-transduced 
or rAAV/GFP-transduced livers, whereas only a few 
ED1-positive macrophages were found in rAAV/HO-
1-transduced livers (Figure 4A). In contrast, there was no 
significant change in the number of  ED2-positive (tissue-
residential) macrophages in the livers of  CCl4-treated rats. 
In consistent with the immunohistochemical stainings, 
detection of  intrahepatic mRNA level by Rnase protection 
assay and serum levels of  MIF by ELISA method showed 
significant reduction of  the expression level of  MIF in 
rAAV/HO-1-treated rats in comparison to non-treatment 
or rAAV/GFP controls (n = 3-5, P < 0.001, Figures 4B 
and 4C). 
To examine the effects of  rAAV/HO-1 on the fi-
brogenic process after liver injury, we next examined the 
Figure 4  A: The representative pictures of pro-inflammatory and pro-fibrogenic 
responses in the livers of rats with or without treatment at the 10th week. Infiltrating 
macrophage (ED1), tissue residential macrophages (ED2), TGF-β1, and activated 
hepatic stellate cells (desmin) were detected by immunohistochemistry; original 
magnification, ×100; B: The profile of pro-inflammatory and profibrogenic 
cytokine expression. The level of mRNA was detected by RNase protection assay 
and was quantified by phosphoimager, n = 3-5, aP<0.05; C: The plasma level of 
macrophage migration inhibitory factor (MIF) was detected by ELISA. The data 
were shown as fold changes of over the level in normal rat, n = 3-5, bP < 0.001.
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expression patterns of  pro-fibrogenic cytokine-TGF-β1, 
which plays an important role in the activation and transi-
tion of  HSCs to myofibroblast-like cells after liver injury. 
Immunohistochemistry showed that TGF-β1 was highly 
expressed in the portal tract areas in the livers of  long-
term CCl4-treated rats. In contrast, only a minimal number 
of  cells expressed TGF-β1 in rAAV/HO-1-transduced 
livers of  rats under the same CCl4 protocol (Figure 4A). 
Parallel to the immunohistochemical stainings, RNase pro-
tection assay also showed significant reduction in the tran-
script level of  TGF-β1 in rAAV/HO-1-transduced livers 
(n = 3-5, P < 0.001, Figure 4B). This finding was associated 
with the decreased number of  activated HSCs (desmin-
positive) in rAAV/HO-1-transduced livers (Figure 4A).
dIScuSSIon
There is a wide range of  factors can result in hepatocel-
lular injury. However, the primary response leading to sub-
sequent pro-inflammatory and pro-fibrogenic responses 
in liver is extraordinary similar [14]. Analysis of  clinical 
parameters based on the treatment of  primary liver dis-
ease showed encouraging results in the decrease of  the 
severity of  liver fibrosis/cirrhosis [15,16]. However, none of  
anti-fibrotic treatment has been shown clinically effective. 
A number of  therapeutic approaches targeting on anti-
oxidant, anti-inflammatory response, suppression of  HSC 
activation, induction of  HSC apoptosis or increase of  the 
degradation of  extracellular matrix have been shown effec-
tive in the attenuation of  the severity of  liver fibrosis/cir-
rhosis in various animal models [14]. Most of  them, howev-
er, cannot easily translate to the clinical setting, because the 
majority of  approaches focus on the single step of  disease 
progression and the clinical situation is far more complex 
than that in the experimental setting. Thus, it is still urged 
to find out a therapeutic target that has multiple effects on 
disease progression and can be applied potentially in the 
clinical setting. 
HO-1-mediated anti-apoptotic and anti-inflammatory 
activities are among the most attractive mechanisms in 
cellular protection [17]. In fact, HO-1 only expresses in a 
subpopulation of  Kupffer cells in normal liver, whereas a 
small amount of  HO-2 is constitutively being expressed 
in hepatocyte [3,4]. None of  them expresses in sinusoidal 
endothelial cells and hepatic stellate cells [3]. However, a 
significant increase in HO-1 expression was observed on 
the whole organ level under stress conditions [4]. In the 
liver with acute injury, HO-1 was expressed in the majority 
of  Kupffer cells and infiltrating macrophages, which might 
function as a feedback loop to control the macrophage 
activation [18-20]. Although the whole HO activity increases 
dramatically, the need for the liver to overcome the insults 
of  cellular injury seems to be relatively insufficient. In-
creasing HO activity by introduction of  exogenous HO-1 
by rAAV/HO-1 in our model that significantly improved 
the long-term outcomes of  CCl4-induced liver cirrhosis 
could be based on (1) the anti-apoptotic effects of  HO-1 
on hepatocyte; (2) the anti-inflammatory effects of  HO-1 
on the control of  the cellular response of  hepatocyte in 
the production of  MIF under stress and/or injury condi-
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tions and the suppression of  the macrophage activation; 
and (3) the anti-fibrogenic effects of  HO-1 on the sup-
pression of   the collagen synthesis and/or proliferation of  
activated HSCs. 
Improvement of  liver function under long-term CCl4 
toxicity by rAAV/HO-1 may reflect the fact that the ex-
pression of  HO-1 in the hepatocyte was able to prevent 
liver damage, which was supported by the down-regulation 
of  pro-apoptotic genes and enhancement of  liver ATP 
level in our model. In acute liver injury and ischemia/
reperfusion injury of  transplanted liver, recent data sug-
gested that the resistance of  HO-1 expressing cells to the 
pro-apoptotic stimuli might be directly through its enzy-
matic product CO and/or indirectly through the induction 
of  the Fe2+-sequestering protein ferritin. Exposure of  CO 
to the primary hepatocyte could prevent the tumor necro-
sis factor-α-mediated and anti-CD95-mediated apoptotic 
events through the down-regulation of  caspase-3 activ-
ity [21], whereas the induction of  ferritin suppressed serum-
deprived or oxidative stress-mediated hepatocyte apoptosis 
by modulation of  intracellular Fe2+ level and inhibition of  
Fe2+-mediated conversion of  hydrogen peroxide into OH− and 
OH through the Fenton reaction [7,22]. In addition to anti-
apoptotic effects, HO-1 could also suppress the produc-
tion of  pro-inflammatory cytokine-MIF production in a 
human primary hepatocyte culture (Tsui TY, et al. unpub-
lished data). This may suggest that HO-1 can function as 
homeostatic molecule in the prevention of  apoptotic event 
and the control of  cellular response. 
HO-1 can be induced in various cell types including 
HSC through direct or indirect mechanisms. Our data are 
consistent with a recent finding in primary human HSC 
culture showing that the induction of  HO-1 expression in 
HSC suppressed the transcript level of  pro-collagen 1α and 
serum-mediated HSC proliferation [23]. This may suggest 
that HO-1 can serve as a negative regulator in the control 
of  HSC activation and proliferation. Thus, less accumula-
tion of  fibrotic elements and prevention of  the develop-
ment of  portal hypertension in rAAV/HO-1-transduced 
animals might reflect the outcomes of  cellular protection, 
anti-inflammatory and anti-fibrogenic responses. Although 
further investigation is needed to clarify the mechanisms 
in more details, increased HO activity in liver and systemic 
effects of  the products of  HO enzymatic activity can be 
the key in the control of  the development of  cirrhosis and 
portal hypertension in our model. 
In conclusion, our data demonstrated that enhance-
ment the HO activity in a stable manner can suppresses 
the pathophysiological changes of  cirrhosis. In addition, 
rAAV-mediated gene transfer may represent an attractive 
approach in controlling the development of  cirrhosis. 
However, further studies should be carried out in order 
to answer the question of  whether the rAAV approach is 
suitable for the hepatitis virus-mediated chronic liver injury 
and the subsequent outcome. 
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